A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC)
出版年份 2022 全文链接
标题
A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC)
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2022-05-23
DOI
10.2217/fon-2022-0285
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
- (2022) Arvind Dasari et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.
- (2022) Masahito Kotaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Molecular Assays and Circulating Tumor DNA in Early Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group ( GICTEG )
- (2021) Arturo Loaiza‐Bonilla et al. ONCOLOGIST
- Total neoadjuvant therapy ( TNT ) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta‐analysis
- (2021) Shuang Liu et al. ONCOLOGIST
- 1415P Performance of a tumor-informed circulating tumor DNA assay from over 250 patients with over 600 plasma time points in esophageal and gastric cancer
- (2021) B.M. Huffman et al. ANNALS OF ONCOLOGY
- Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer
- (2021) Jun Gong et al. Cancers
- Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
- (2021) Tenna Vesterman Henriksen et al. CLINICAL CANCER RESEARCH
- NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.
- (2020) Van K. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline
- (2020) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial
- (2020) W.O. de Steur et al. ANNALS OF ONCOLOGY
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- (2019) Salah-Eddin Al-Batran et al. LANCET
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
- (2018) Astrid E. Slagter et al. BMC CANCER
- Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
- (2017) Karyn A. Goodman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Clinically Meaningful Use of Blood Tumor Markers in Oncology
- (2016) Stefan Holdenrieder et al. Biomed Research International
- TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
- (2015) Trevor Leong et al. BMC CANCER
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More